Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-1654 versus palivizumab for RSV prevention in high-risk infants and children
2020-005996-11Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing MK-1654 with Palivizumab control (2 arms). Primary endpoint: Percentage of participants with solicited injection-site adverse events in RSV Season 1. Started Jul 2021; status: active.
02
Drugs
clesrovimab-cforpalivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-005996-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005996-11.